Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cellectar Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cellectar Biosciences's regulatory disclosures and financial reporting.
Cellectar Biosciences, Inc. has a large shareholder group reporting beneficial ownership of its common stock. Investment manager Caligan Partners LP and David Johnson, its Managing Partner, report beneficial ownership of 469,998 shares of Cellectar common stock, representing 5.9% of the outstanding shares.
These shares are held in certain funds and accounts managed by Caligan, with shared voting and dispositive power over all 469,998 shares and no sole voting or dispositive power. The percentage ownership is based on 7,991,812 shares outstanding as of May 12, 2026, as reported in Cellectar’s Form 10-Q for the quarter ended March 31, 2026.
SilverArc Capital Management, LLC and Devesh Gandhi report beneficial ownership of 851,285 shares of Cellectar Biosciences Inc Class A Common Stock, representing 9.99% of the class. All voting and dispositive authority over these shares is reported as shared, with no sole voting or dispositive power.
SilverArc-related accounts, including SilverArc Capital Alpha Fund I, LP and SilverArc Capital Alpha Fund II, LP, collectively hold 321,728 shares of common stock and 1,132,074 exercisable warrants, subject to a 9.99% beneficial ownership blocker. The ownership percentage is calculated using 7,991,812 shares outstanding as stated in the issuer’s proxy statement dated May 28, 2026.
StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross report beneficial ownership of Cellectar Biosciences common stock. They may be deemed to beneficially own 845,740 shares of common stock, including shares issuable upon exercise of pre-funded warrants, representing 9.99% of the class.
The position consists of 354,938 shares of common stock and 490,802 shares issuable upon exercise of pre-funded warrants that are subject to a 9.99% Beneficial Ownership Limitation. Ownership is reported as shared voting power over 779,976 shares and shared dispositive power over 845,740 shares, based on 7,975,069 shares outstanding as of June 2, 2026 plus the exercisable warrant shares.
Cellectar Biosciences, Inc. shareholder disclosure: institutional investor Balyasny Asset Management L.P. and related entities reported beneficial ownership of Cellectar common stock. Through Atlas Private Holdings (Cayman) Ltd., they may be deemed to beneficially own 798,382 shares of common stock.
This position represents approximately 9.99% of the outstanding shares, based on 7,991,812 shares outstanding as of May 12, 2026. The reported amount consists of 220,000 shares plus 578,382 shares issuable upon exercise of 1,289,432 warrants, all subject to a 9.99% Beneficial Ownership Limitation that blocks warrant exercises which would push ownership above that threshold. The reporting persons have sole voting and dispositive power over the 798,382 shares and no shared power.
Cellectar Biosciences, Inc. has a significant shareholder group led by Bleichroeder entities and Andrew Gundlach. Bleichroeder LP, an investment adviser registered under the Investment Advisers Act of 1940, is deemed the beneficial owner of 808,300 common shares, representing 9.99% of Cellectar’s common stock believed to be outstanding. Bleichroeder Holdings LLC and Andrew Gundlach are also listed as reporting persons, each with sole voting and sole dispositive power over 808,300 shares, and no shared voting or dispositive power. The shares are held for various advisory clients of Bleichroeder, and those clients have the right to receive, and ultimately direct, the receipt of dividends and sale proceeds from these securities.
Cellectar Biosciences reported second quarter 2026 results and provided an update on its oncology pipeline. For the quarter ended June 30, 2026, the company recorded a net loss of $6,930,653, compared with $5,447,911 a year earlier. Operating expenses were $7,196,012, including $4,557,383 in research and development and $2,638,629 in general and administrative costs.
On the balance sheet, Cellectar reported cash and cash equivalents of $33,993,982 and total assets of $36,639,086 as of June 30, 2026, with stockholders’ equity of $29,871,833. The company initiated site activation for a confirmatory Phase 3 study of iopofosine I 131 in Waldenström macroglobulinemia, with a New Drug Application submission planned for mid‑2027 under the FDA’s accelerated approval program. It also presented Phase 2b CLOVER WaM data, began enrolling and dosing patients in a Phase 1b trial of CLR 125 in triple‑negative breast cancer, and reported publication of Phase 1 data in the journal Cancers.
Cellectar Biosciences, Inc. reported a net loss of $6.9M for the quarter and $12.6M for the six months ended June 30, 2026, similar to the prior year, as it continues late‑stage development of its radioconjugate cancer therapies. Operating expenses were $7.2M for the quarter, driven by $4.6M in research and development and $2.6M in general and administrative costs.
Cash and cash equivalents increased to $34.0M from $13.2M at year‑end 2025, primarily from a May 2026 registered direct offering and concurrent private placement providing $35.0M gross ($31.7M net) upfront and up to $105M in milestone-based securities. The company used $10.9M of cash in operating activities in the first half. Management discloses that, despite this financing, there is substantial doubt about its ability to continue as a going concern beyond the second quarter of 2027 without additional capital or strategic actions. At June 30, 2026, stockholders’ equity was $29.9M and 8,252,108 common shares were outstanding.
Empery Asset Management, LP and Ryan M. Lane report beneficial ownership of Cellectar Biosciences, Inc. Common Stock through funds managed by Empery. They report beneficial ownership of 864,090 shares, including 674,485 shares issuable upon exercise of warrants.
The filing states this represents 9.99% of the class, calculated based on 7,975,069 shares of Common Stock outstanding as of June 2, 2026. The warrants are subject to a 9.99% Beneficial Ownership Limitation (the “Blocker”), so the reporting persons cannot exercise warrants if doing so would raise their beneficial ownership above that threshold.
Empery Asset Management, LP may be deemed to beneficially own the securities held by the Empery funds, and Lane may be deemed to beneficially own them through his control positions. Each reporting person disclaims beneficial ownership of securities owned by the others.
Cellectar Biosciences, Inc. reported that consultant Loren Stefan received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.6900 per share and expire on July 8, 2036. The award vests in full on July 8, 2027, subject to continued service through that date. Following this grant, Stefan holds 15,000 stock options directly.
Cellectar Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on July 7, 2026. Stockholders elected Class III directors Andrew Gu and Douglas J. Swirsky to new three-year terms. They approved an amendment to the 2021 Stock Incentive Plan to increase shares reserved for issuance by 2,000,000 shares of common stock. Stockholders also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026 and, on a non-binding advisory basis, approved executive officer compensation. In addition, stockholders approved the exercise of warrants to purchase up to 39,618,078 shares of common stock under Nasdaq rules, making a planned adjournment proposal moot.